fingolimod hydrochloride has been researched along with Libman-Sacks Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, S; Chen, J; Fan, W; Huang, T; Kang, J; Tian, J; Wang, J; Wang, Y; Xu, H | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Cao, K; Li, L; Shi, D; Shi, M; Tian, T; Wen, S; Yao, S; Zhang, M; Zhou, H; Zhu, X | 1 |
| Kusnecov, AW | 1 |
| Amano, E; Amano, H; Ando, S; Hirose, S; Hou, R; Lin, Q; Minowa, K; Morimoto, S; Nakano, S; Nakiri, Y; Ohtsuji, M; Takasaki, Y; Tokano, Y; Tsurui, H; Watanabe, T | 1 |
| Fujimura, A; Hirata, D; Iwamoto, M; Kamimura, T; Kano, S; Kobayashi, E; Masuyama, J; Minota, S; Okazaki, H; Sato, H; Yoshio, T | 1 |
6 other study(ies) available for fingolimod hydrochloride and Libman-Sacks Disease
| Article | Year |
|---|---|
S1P/S1PR1 axis promotes macrophage M1 polarization through NLRP3 inflammasome activation in Lupus nephritis.
Topics: Animals; Fingolimod Hydrochloride; Inflammasomes; Inflammation; Lupus Erythematosus, Systemic; Lupus Nephritis; Macrophages; Mice; Mice, Inbred MRL lpr; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sphingosine-1-Phosphate Receptors | 2023 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus.
Topics: Animals; Brain; Cytokines; Depression; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunologic Factors; Lupus Erythematosus, Systemic; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Quality of Life; Signal Transduction; T-Lymphocytes | 2018 |
From the head of a caterpillar: A possible treatment for neuropsychiatric sequelae of autoimmune disease.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Lupus Erythematosus, Systemic; Mice | 2018 |
FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice.
Topics: Animals; Antibodies, Antinuclear; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphocytes; Mesangial Cells; Mice; Monocytes; Propylene Glycols; Sphingosine; Spleen | 2010 |
Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Apoptosis; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; DNA; Female; Fingolimod Hydrochloride; Flow Cytometry; Immunoglobulin G; Immunosuppressive Agents; Interleukin-2; Kidney Glomerulus; Longevity; Lupus Erythematosus, Systemic; Lymphoid Tissue; Methylprednisolone; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Propylene Glycols; Sphingosine; T-Lymphocytes | 2002 |